Sigilon Therapeutics
(NASDAQ) SGTX
Sigilon Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$17.65M
Net Income (TTM)
$29.57M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
SGTX News
SGTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sigilon Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
62
CEO
Rogério Vivaldi Coelho, MD, MBA
Website
www.sigilon.comHeadquarters
Cambridge, MA 02142, US
SGTX Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-75%
Return on Capital
-78%
Return on Assets
-50%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$12.94M
Operating Income
$43.67M
EBITDA
$38.88M
Operating Cash Flow
$51.47M
Capital Expenditure
$537.00K
Free Cash Flow
$52.01M
Cash & ST Invst.
$69.63M
Total Debt
$28.06M
Sigilon Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.90M
+104.6%
Gross Profit
$5.90M
+104.6%
Gross Margin
100.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
62
N/A
Net Income
$7.51M
+48.8%
EBITDA
$6.89M
+48.9%
Quarterly Fundamentals
Net Cash
$27.51M
-51.5%
Accounts Receivable
$6.86M
+29717.4%
Inventory
$250.00K
N/A
Long Term Debt
$2.87M
-87.0%
Short Term Debt
$4.52M
-52.1%
Return on Assets
-49.79%
N/A
Return on Invested Capital
-77.58%
N/A
Free Cash Flow
$4.29M
+71.2%
Operating Cash Flow
$4.16M
+71.9%